Brain-Delivered MOTS-c Influences Reproductive Hormones Differently in Obese and Lean Rats
Background
The mitochondrial-derived peptide MOTS-c is increasingly recognized for its crucial roles in metabolic regulation, cellular energy homeostasis, and even longevity. Dysregulation of reproductive hormones is a common and debilitating consequence of obesity, contributing to conditions such as infertility, hypogonadism, and polycystic ovary syndrome (PCOS). While MOTS-c's systemic metabolic benefits are well-documented, its direct impact on the central nervous system's regulation of the reproductive axis, particularly in varying metabolic states like obesity, remains an underexplored area of research.
Results
The study revealed significant and differential effects of central MOTS-c infusion on reproductive hormone profiles, particularly pronounced in the obese rats. In this group, MOTS-c treatment led to a substantial normalization of several hormone levels. > Specifically, central MOTS-c infusion in obese rats resulted in a remarkable 43% increase in serum testosterone levels (p<0.01) and a significant 35% reduction in estradiol levels (p<0.05) when compared to obese rats receiving saline. Conversely, in the lean control rats, MOTS-c administration induced a 15% decrease in LH levels (p<0.05) and a 10% increase in FSH levels (p<0.05), suggesting a more nuanced modulatory role in a metabolically healthy state. Importantly, no statistically significant changes were observed in either body weight or daily food intake across any of the treatment groups, indicating that the observed hormonal shifts were a direct central effect of MOTS-c rather than secondary to general metabolic changes. These findings underscore a critical, distinct central regulatory role for MOTS-c on the hypothalamic-pituitary-gonadal (HPG) axis, offering a potential therapeutic avenue for obesity-related reproductive dysfunction.
Why It Matters
This study provides compelling and novel evidence that central MOTS-c administration can significantly modulate reproductive hormones, with distinct effects depending on the metabolic state of the individual. The ability of MOTS-c to improve testosterone and estradiol balance in obese rats suggests its potential as a novel therapeutic target for obesity-induced reproductive disorders, such as hypogonadism or PCOS, which currently lack highly effective treatments. Further research, including detailed investigations into the specific neural pathways and receptors involved, as well as dose-response studies in larger animal models, could pave the way for future human clinical trials exploring MOTS-c as a treatment for various reproductive health issues.